The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.
 
Milind M. Javle
Consulting or Advisory Role - incyte; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Saeed Sadeghi
No Relationships to Disclose
 
Anthony B. El-Khoueiry
Honoraria - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Merck
 
Lipika Goyal
No Relationships to Disclose
 
Philip Agop Philip
Honoraria - Array BioPharma; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Ipsen; Merck; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Ipsen; Merck; TriSalus Life Sciences
Speakers' Bureau - Bayer; Celgene; Ipsen
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche; Gilead Sciences; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Ivan Borbath
Consulting or Advisory Role - Novartis (Inst)
Research Funding - Celgene (Inst); Ipsen (Inst); Novartis (Inst)
 
Teresa Macarulla
Consulting or Advisory Role - Baxalta; Baxter; Celgene; Incyte; Ipsen; Lilly; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Shire
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millennium (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Merck; Sanofi; SERVIER
 
Wei-Peng Yong
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Bristol-Myers Squibb; Ipsen; Novartis
Speakers' Bureau - Eisai; Lilly; Sanofi/Aventis; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Pfizer
 
Suebpong Tanasanvimon
No Relationships to Disclose
 
Amit Pande
Employment - QED Therapeutics
Stock and Other Ownership Interests - Bridgebio; QED Therapeutics
 
Gary Li
Employment - QED Therapeutics
 
Michael Howland
Employment - Denali Therapeutics; Genentech; QED Therapeutics
Stock and Other Ownership Interests - Aduro Biotech; Bridgebio; Halozyme; Incyte; Merck; Roche
 
Craig Berman
Employment - QED Therapeutics
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Bristol-Myers Squibb; Celgene; CytomX Therapeutics (I); Debiopharm Group; Eisai; Exelixis; Flatiron Health; Flatiron Health; Genoscience Pharma; Gilead Sciences; Ipsen; Janssen (I); LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; Pfizer (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; Silenseed (I); Sillajen; SOBI (I); Targovax (I); twoXAR; Vicus Therapeutics; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); Novartis (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris